Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

CMC PHARMACEUTICALS

Filed by CAPITOL COUNSEL LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 17, 2026
Income
$40,000.00
Expenses
Not reported
Filing UUID
f284d9cb-a534-42ce-8fcd-ff317eff03e8
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection funding.

DEF · Defense

Issues related to the FY27 National Defense Authorization Act (H.R. 8800/ S. 4784) and Defense Appropriations.

Literal federal measure citations: H.R. 8800, S. 4784

GOV · Government Issues

Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection policy.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.